» Articles » PMID: 17448021

Prognostic Significance of the Wnt Signalling Pathway Molecules APC, Beta-catenin and E-cadherin in Colorectal Cancer: a Tissue Microarray-based Analysis

Overview
Journal Histopathology
Date 2007 Apr 24
PMID 17448021
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To investigate dysregulation of the wnt signalling pathway by assessing beta-catenin expression/increasing expression and loss of cytoplasmic adenomatous polyposis coli (APC) and membranous E-cadherin in colorectal cancer (CRC) and determining the prognostic significance of these variables.

Methods And Results: Unselected, non-consecutive CRC resections (n = 1420) were subdivided into three groups: mismatch repair (MMR)-proficient, MLH1- and presumed hereditary non-polyposis colonic cancer (HNPCC). Immunohistochemical analysis of beta-catenin expression (0% versus > 0%) and increasing expression (increasing percentage-positivity) and loss of APC and E-cadherin was performed using the tissue microarray technique. In MMR-proficient CRC, increased nuclear beta-catenin expression and loss of membranous E-cadherin were independently associated with higher N stage (P = 0.03 and < 0.0001), vascular invasion (P < 0.01 and < 0.001) and worse survival (P < 0.01 and < 0.001). Additionally, there was an association between loss of membranous E-cadherin and higher T stage (P = 0.03). In MLH1- CRC, loss of membranous E-cadherin was associated with higher N stage (P = 0.05) and worse survival (P = 0.03). In presumed HNPCC CRC nuclear beta-catenin and membranous E-cadherin were not associated with tumour progression or worse survival. In all CRC subsets loss of cytoplasmic APC was not associated with clinicopathological features.

Conclusions: Increasing nuclear beta-catenin expression and loss of membranous E-cadherin are independent, adverse prognostic factors in MMR-proficient and MLH1- CRC.

Citing Articles

Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy.

Chen H, Zhang J, Hao Q, Wu X, Guo J, Huang C Int J Colorectal Dis. 2024; 39(1):99.

PMID: 38926205 PMC: 11208236. DOI: 10.1007/s00384-024-04672-1.


Prime Editing and DNA Repair System: Balancing Efficiency with Safety.

Daliri K, Hescheler J, Pfannkuche K Cells. 2024; 13(10.

PMID: 38786078 PMC: 11120019. DOI: 10.3390/cells13100858.


E-Cadherin Expression Varies Depending on the Location within the Primary Tumor and Is Higher in Colorectal Cancer with Lymphoid Follicles.

Markowski A, Ustymowicz K, Markowska A, Romanczyk W, Guzinska-Ustymowicz K Cancers (Basel). 2023; 15(12).

PMID: 37370870 PMC: 10296849. DOI: 10.3390/cancers15123260.


E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis.

Chang Y, Huang G, Chen Y, Huang K, Chen Y, Lin C BMC Cancer. 2023; 23(1):569.

PMID: 37340370 PMC: 10283306. DOI: 10.1186/s12885-023-10980-6.


Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.

Demarchi G, Perrone S, Esper Romero G, De Bonis C, Casasco J, Sevlever G Front Endocrinol (Lausanne). 2022; 13:870172.

PMID: 35928898 PMC: 9344046. DOI: 10.3389/fendo.2022.870172.